Immuno-Oncology - Global Strategic Business Report

Report
224 Pages
July 2024
Region: Global
Global Industry Analysts, Inc
ID: 5309486

The global market for Immuno-Oncology is estimated at US$27.5 Billion in 2023 and is projected to reach US$78.3 Billion by 2030, growing at a CAGR of 16.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

Market Growth: Understand the significant growth trajectory of the Immune Checkpoint Inhibitors-based Treatment segment, which is expected to reach US$67.1 Billion by 2030 with a CAGR of a 16.1%. The Immune System Modulators-based Treatment segment is also set to grow at 15.8% CAGR over the next 7 years.
Regional Analysis: Gain insights into the U.S. market, estimated at $8.4 Billion in 2023, and China, forecasted to grow at an impressive 15.3% CAGR to reach $13.3 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global Immuno-Oncology Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Immuno-Oncology Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global Immuno-Oncology Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as AbbVie, Inc., Aduro BioTech, Inc., Amgen, Inc., and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 102 Featured):

AbbVie, Inc.
Aduro BioTech, Inc.
Amgen, Inc.
AstraZeneca PLC
Bavarian Nordic A/S
Bristol-Myers Squibb Company
Celgene Corporation
Celldex Therapeutics, Inc.
Eli Lilly and Company
EMD Serono, Inc.
F. Hoffmann-La Roche AG
Galena Biopharma, Inc.
Gilead Sciences, Inc.
ImmunoCellular Therapeutics Ltd.
Incyte Corporation
Johnson & Johnson
Merck & Co., Inc.
Novartis International AG
Pfizer, Inc.
Prometheus Laboratories, Inc.
Sanofi SA

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
Immuno-Oncology - Global Key Competitors Percentage Market Share in 2024 (E)
Global Economic Update
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Immuno-Oncology Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
Table 2: World Recent Past, Current & Future Analysis for Immuno-Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 3: World 7-Year Perspective for Immuno-Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
Table 4: World Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 5: World 7-Year Perspective for Immune Checkpoint Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
Table 6: World Recent Past, Current & Future Analysis for Immune System Modulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 7: World 7-Year Perspective for Immune System Modulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
Table 8: World Recent Past, Current & Future Analysis for Cancer Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 9: World 7-Year Perspective for Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
Table 10: World Recent Past, Current & Future Analysis for Oncolytic Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 11: World 7-Year Perspective for Oncolytic Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
Table 12: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 13: World 7-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES

Immuno-Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Table 14: USA Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 15: USA 7-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2024 & 2030

CANADA

Table 16: Canada Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 17: Canada 7-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2024 & 2030

JAPAN

Immuno-Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
Table 18: Japan Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 19: Japan 7-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2024 & 2030

CHINA

Immuno-Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
Table 20: China Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 21: China 7-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2024 & 2030

EUROPE

Immuno-Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Table 22: Europe Recent Past, Current & Future Analysis for Immuno-Oncology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 23: Europe 7-Year Perspective for Immuno-Oncology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
Table 24: Europe Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 25: Europe 7-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2024 & 2030

FRANCE

Immuno-Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
Table 26: France Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 27: France 7-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2024 & 2030

GERMANY

Immuno-Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
Table 28: Germany Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 29: Germany 7-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2024 & 2030

ITALY

Table 30: Italy Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 31: Italy 7-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2024 & 2030

UNITED KINGDOM

Immuno-Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
Table 32: UK Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 33: UK 7-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2024 & 2030

REST OF EUROPE

Table 34: Rest of Europe Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 35: Rest of Europe 7-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2024 & 2030

ASIA-PACIFIC

Immuno-Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
Table 36: Asia-Pacific Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 37: Asia-Pacific 7-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2024 & 2030

REST OF WORLD

Table 38: Rest of World Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 39: Rest of World 7-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2024 & 2030

IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

AbbVie, Inc.
Aduro BioTech, Inc.
Amgen, Inc.
AstraZeneca PLC
Bavarian Nordic A/S
Bristol-Myers Squibb Company
Celgene Corporation
Celldex Therapeutics, Inc.
Eli Lilly and Company
EMD Serono, Inc.
F. Hoffmann-La Roche AG
Galena Biopharma, Inc.
Gilead Sciences, Inc.
ImmunoCellular Therapeutics Ltd.
Incyte Corporation
Johnson & Johnson
Merck & Co., Inc.
Novartis International AG
Pfizer, Inc.
Prometheus Laboratories, Inc.
Sanofi SA

Table Information

Report Attribute	Details
No. of Pages	224
Published	July 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 27.5 Billion
Forecasted Market Value ( USD ) by 2030	$ 78.3 Billion
Compound Annual Growth Rate	16.1%
Regions Covered	Global

PURCHASE OPTIONS

Single User License PDF

1 - 10 User License PDF

Enterprise License PDF

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4718EUR$4,950USD£3,983GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€8965EUR$9,405USD£7,567GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€14155EUR$14,850USD£11,948GBP

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 102 Featured):

MarketGlass Platform

Table of Contents

Companies Mentioned (Partial List)

Table Information

Related Topics

Related Reports

Immuno-Oncology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Global Immuno-oncology Market

Immuno-Oncology Drugs Global Market Report 2024

Viral Vectors in Cancer Immunotherapy. International Review of Cell and Molecular Biology Volume 379

Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F